Supplementary Table S1A. Characteristics of the study population by the presence of deposits of complement factors

	Glomerular deposits of C1q			Glomerular deposits of C3		
	Absent	**Present**	***P***	**Absent**	**Present**	***P***
Number of patients, *n*	37	146		18	165	
Age, median (iqr), years	35 (28-44)	36 (26-45)	0.87	36 (31-54)	35 (26-45)	0.16
Female sex, %	89.2	82.2	0.30	77.8	84.2	0.48
Race/ethnicity, %			0.19			0.28
White	46.0	33.6		38.9	35.8	
Black	37.8	30.1		50.0	29.7	
Hispanic	8.1	20.6		5.6	19.4	
Asian	8.1	12.3		5.6	12.1	
Other or unknown	0.0	3.4		0.0	3.0	
Past medical history, %						
Hypertension	64.9	56.9	0.38	72.2	57.0	0.21
Diabetes mellitus	2.7	5.5	0.49	0.0	5.5	0.31
Current hypertension, %	19.4	32.0	0.17	**53.3**	**27.1**	**0.03**
Duration of SLE, median (iqr), years	5.8 (1.8-11.2)	2.9 (0.4-10.5)	0.21	3.8 (1.9-7.2)	3.6 (0.5-10.7)	0.82
SLICC/ACR damage index, median (iqr)[a]	3 (1-5)	2 (0-4)	0.07	4 (1-5)	2 (1-4)	0.10
Medication, %						
ACE inhibitors	22.2	30.0	0.36	11.1	30.4	0.09
NSAIDs	22.2	23.9	0.84	33.3	22.3	0.30
HCQ	58.3	49.2	0.33	72.2	48.7	0.06
High-dose corticosteroids[b]	30.6	30.8	0.98	33.3	30.4	0.80
Immunosuppressives[c]	11.1	23.9	0.10	5.6	23.0	0.09
Haemoglobin, median (iqr), g/dl	11.5 (10.1-12.3)	10.6 (9.2-12.0)	0.09	12.0 (8.7-12.3)	10.8 (9.3-12.0)	0.32
Serum albumin, median (iqr), g/dl	3.4 (2.9-4.0)	3.1 (2.7-3.5)	0.06	3.4 (2.9-4.1)	3.2 (2.7-3.5)	0.13
Serum creatinine, median (iqr), mg/dl	0.9 (0.7-1.5)	0.9 (0.7-1.2)	0.69	1.0 (0.7-2.0)	0.9 (0.7-1.3)	0.23
eGFR, median (iqr), ml/min/1.73 m^2	91 (44-119)	93 (58-119)	0.77	95 (28-114)	93 (58-120)	0.35
Proteinuria, %[d]	69.7	74.2	0.60	73.3	73.2	0.99
Serum C3, median (iqr), mg/dl	**83 (57-116)**	**57 (40-73)**	**< 0.001**	**97 (64-126)**	**57 (42-80)**	**0.004**
Serum C4, median (iqr), mg/dl	**13 (8-23)**	**8 (6-13)**	**0.003**	**15 (9-23)**	**9 (6-13)**	**0.04**
Anti-dsDNA antibodies, %	75.8	82.5	0.38	71.4	82.1	0.33
aPL antibodies, %[e]	55.6	31.1	0.05	55.6	33.7	0.20
Glomerulosclerosis, median (iqr), %	9 (1-31)	5 (0-18)	0.08	10 (0-41)	5 (0-20)	0.13
IF/TA, median (iqr), %	10 (0-20)	10 (0-20)	0.91	10 (0-35)	10 (0-20)	0.47
Any tubulointerstitial inflammation, %	16.2	13.8	0.71	16.7	14.0	0.76
Moderate to severe vascular damage, %	40.5	34.3	0.48	50.0	33.9	0.18
Pathological activity index, median (iqr)[f]	**3 (1-8)**	**7 (2-11)**	**0.04**	3 (1-8)	6 (2-11)	0.18
Pathological chronicity index, median (iqr)[g]	2 (1-5)	2 (0-3)	0.19	**4 (1-5)**	**2 (0-3)**	**0.05**

Supplementary Table S1B. Characteristics of the study population by the presence of deposits of complement factors

	Tubular deposits of C1q			Tubular deposits of C3		
	Absent	**Present**	***P***	**Absent**	**Present**	***P***
Number of patients, *n*	147	36		100	83	
Age, median (iqr), years	36 (26-45)	32 (29-43)	0.75	36 (26-44)	36 (27-47)	0.54
Female sex, %	83.7	83.3	0.96	79.0	89.2	0.07
Race/ethnicity, %			0.13			0.47
White	39.5	22.2		40.0	31.3	
Black	30.6	36.1		29.0	34.9	
Hispanic	18.4	16.7		20.0	15.7	
Asian	8.8	22.2		9.0	14.5	
Other or unknown	2.7	2.8		2.0	3.6	
Past medical history, %						
Hypertension	59.2	55.6	0.69	62.0	54.2	0.29
Diabetes mellitus	4.1	8.3	0.29	6.0	3.6	0.46
Current hypertension, %	**22.7**	**58.1**	**< 0.001**	**23.0**	**37.5**	**0.046**
Duration of SLE, median (iqr), years	4.0 (0.6-11.9)	3.4 (0.3-7.0)	0.32	3.3 (0.5-11.9)	4.2 (0.7-9.5)	0.76
SLICC/ACR damage index, median (iqr)[a]	2 (1-4)	2 (0-5)	0.90	2 (1-4)	2 (1-4)	0.67
Medication, %						
ACE inhibitors	26.5	36.7	0.26	27.5	29.3	0.79
NSAIDs	25.0	16.7	0.33	23.1	24.0	0.89
HCQ	52.9	43.3	0.34	53.9	48.0	0.45
High-dose corticosteroids[b]	30.9	30.0	0.92	29.7	32.0	0.75
Immunosuppressives[c]	19.9	26.7	0.41	19.8	22.7	0.65
Haemoglobin, median (iqr), g/dl	**11.0 (9.7-12.3)**	**9.8 (8.9-10.6)**	**< 0.001**	11.0 (9.7-12.2)	10.5 (9.2-12.0)	0.20
Serum albumin, median (iqr), g/dl	**3.3 (2.9-3.6)**	**2.8 (2.5-3.2)**	**0.001**	**3.4 (2.9-3.7)**	**3.0 (2.5-3.5)**	**0.008**
Serum creatinine, median (iqr), mg/dl	0.9 (0.7-1.2)	1.0 (0.7-1.6)	0.36	0.9 (0.7-1.2)	0.9 (0.7-1.5)	0.51
eGFR, median (iqr), ml/min/1.73 m^2	93 (60-120)	81 (44-118)	0.34	93 (60-122)	90 (46-118)	0.38
Proteinuria, %[d]	73.0	74.2	0.89	71.8	75.0	0.65
Serum C3, median (iqr), mg/dl	**64 (47-91)**	**47 (36-57)**	**< 0.001**	**69 (44-103)**	**57 (43-68)**	**0.005**
Serum C4, median (iqr), mg/dl	**10 (7-16)**	**7 (6-9)**	**0.006**	10 (6-18)	8 (6-12)	0.12
Anti-dsDNA antibodies, %	78.5	93.1	0.07	**75.3**	**88.6**	**0.03**
aPL antibodies, %[e]	38.4	26.3	0.33	39.2	31.7	0.46
Glomerulosclerosis, median (iqr), %	5 (0-22)	6 (0-20)	0.97	5 (0-23)	5 (0-18)	0.72
IF/TA, median (iqr), %	10 (0-20)	10 (3-23)	0.27	10 (0-20)	10 (0-20)	0.73
Any tubulointerstitial inflammation, %	12.3	22.2	0.13	12.1	16.9	0.36
Moderate to severe vascular damage, %	33.3	44.4	0.21	**29.0**	**43.4**	**0.04**
Pathological activity index, median (iqr)[f]	**4 (1-9)**	**10 (6-13)**	**0.003**	**5 (1-9)**	**7 (2-11)**	**0.03**
Pathological chronicity index, median (iqr)[g]	2 (0-3)	2 (1-4)	0.39	2 (0-3)	2 (1-4)	0.11

Supplementary Table S1C. Characteristics of the study population by the presence of deposits of complement factors

	Vascular deposits of C1q			Vascular deposits of C3		
	Absent	**Present**	***P***	**Absent**	**Present**	***P***
Number of patients, *n*	145	38		52	131	
Age, median (iqr), years	36 (26-45)	35 (26-45)	0.92	35 (26-43)	36 (26-46)	0.70
Female sex, %	83.5	84.2	0.91	78.9	85.5	0.27
Race/ethnicity, %			0.42			0.36
White	37.9	29.0		30.8	38.2	
Black	29.0	42.1		36.5	29.8	
Hispanic	18.6	15.8		23.1	16.0	
Asian	11.0	13.2		9.6	12.2	
Other or unknown	3.5	0.0		0.0	3.8	
Past medical history, %						
Hypertension	58.6	57.9	0.94	57.7	58.8	0.89
Diabetes mellitus	5.5	2.6	0.46	5.8	4.6	0.74
Current hypertension, %	**24.6**	**46.0**	**0.01**	23.8	31.6	0.34
Duration of SLE, median (iqr), years	5.0 (0.6-11.9)	1.9 (0.4-5.6)	0.12	3.6 (0.5-9.3)	3.8 (0.6-11.5)	0.31
SLICC/ACR damage index, median (iqr)[a]	2 (1-4)	2 (1-5)	0.53	2 (1-4)	2 (1-5)	0.89
Medication, %						
ACE inhibitors	27.6	31.3	0.68	20.8	31.4	0.17
NSAIDs	22.4	28.1	0.49	33.3	19.5	0.06
HCQ	54.5	37.5	0.08	62.5	46.6	0.06
High-dose corticosteroids[b]	30.6	31.3	0.94	20.8	34.8	0.08
Immunosuppressives[c]	20.2	25.0	0.55	14.6	23.7	0.19
Haemoglobin, median (iqr), g/dl	**11.0 (9.7-12.2)**	**9.7 (8.8-11.1)**	**0.004**	11.0 (9.6-12.4)	10.8 (9.3-12.0)	0.40
Serum albumin, median (iqr), g/dl	**3.3 (2.8-3.6)**	**2.9 (2.4-3.3)**	**0.01**	3.3 (2.8-3.9)	3.2 (2.7-3.5)	0.19
Serum creatinine, median (iqr), mg/dl	0.9 (0.7-1.3)	0.9 (0.6-1.2)	0.36	0.90 (0.70-1.50)	0.9 (0.7-1.2)	0.86
eGFR, median (iqr), ml/min/1.73 m^2	92 (57-118)	93 (51-123)	0.36	99 (46-124)	90 (58-118)	0.66
Proteinuria, %[d]	74.4	69.4	0.56	**61.0**	**77.6**	**0.04**
Serum C3, median (iqr), mg/dl	**64 (46-90)**	**48 (37-63)**	**0.003**	65 (44-106)	58 (43-80)	0.20
Serum C4, median (iqr), mg/dl	**10 (7-17)**	**7 (6-9)**	**0.001**	11 (7-16)	8 (6-13)	0.07
Anti-dsDNA antibodies, %	**77.6**	**94.1**	**0.03**	71.7	85.0	0.05
aPL antibodies, %[e]	36.5	33.3	0.80	44.4	32.3	0.27
Glomerulosclerosis, median (iqr), %	5 (0-22)	8 (0-22)	0.72	5 (0-23)	5 (0-21)	0.76
IF/TA, median (iqr), %	10 (0-20)	10 (5-20)	0.09	10 (0-20)	10 (0-20)	0.67
Any tubulointerstitial inflammation, %	13.2	18.4	0.41	17.7	13.0	0.42
Moderate to severe vascular damage, %	32.4	47.4	0.09	25.0	39.7	0.06
Pathological activity index, median (iqr)[f]	5 (1-10)	7 (2-13)	0.10	4 (1-11)	7 (2-11)	0.12
Pathological chronicity index, median (iqr)[g]	2 (0-3)	3 (1-4)	0.08	2 (1-3)	2 (1-3)	0.78

[a] Excluding the parameters reflecting renal damage, maximum score of 37. [b] Prednisone ≥ 20 mg/d or equivalent. [c] Including azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate, rituximab. [d] Protein-creatinine ratio ≥ 1 g/g. [e] aCL antibodies, anti-β2-glycoprotein antibodies, or lupus anticoagulant detected at least twice. [f] Maximum score of 24. [g] Maximum score of 12. ACE: angiotensin-converting enzyme; IF/TA: interstitial fibrosis and tubular atrophy; iqr: interquartile range.

Supplementary Table S2. Characteristics of the study population by the intensity of glomerular deposits of complement factors

	Glomerular deposits of C1q		Glomerular deposits of C3	
	Correlation coefficient[h]	***P***	**Correlation coefficient[h]**	***P***
Age, median (iqr), years	-0.13	0.07	**-0.16**	**0.04**
Female sex, %	-0.08	0.30	0.07	0.35
Race/ethnicity, %				
White	**-0.16**	**0.03**	-0.02	0.78
Black	-0.09	0.21	-0.11	0.16
Hispanic	**0.16**	**0.03**	0.06	0.43
Asian	**0.16**	**0.04**	0.08	0.31
Other or unknown	0.05	0.51	0.09	0.30
Past medical history, %				
Hypertension	-0.12	0.10	-0.13	0.07
Diabetes mellitus	0.06	0.46	-0.05	0.47
Current hypertension, %	**0.16**	**0.04**	-0.04	0.58
Duration of SLE, median (iqr), years	-0.13	0.09	-0.05	0.53
SLICC/ACR damage index, median (iqr)[a]	**-0.18**	**0.02**	**-0.20**	**0.01**
Medication, %				
ACE inhibitors	0.04	0.60	0.12	0.13
NSAIDs	0.02	0.83	0.05	0.56
HCQ	-0.06	0.47	-0.02	0.76
High-dose corticosteroids[b]	0.07	0.40	0.07	0.40
Immunosuppressives[c]	**0.20**	**0.009**	**0.20**	**0.009**
Haemoglobin, median (iqr), g/dl	**-0.18**	**0.02**	**-0.21**	**0.008**
Serum albumin, median (iqr), g/dl	**-0.21**	**0.008**	**-0.16**	**0.04**
Serum creatinine, median (iqr), mg/dl	-0.08	0.29	0.00	1.00
eGFR, median (iqr), ml/min/1.73 m^2	0.09	0.25	-0.01	0.92
Proteinuria, %[d]	0.03	0.76	0.04	0.62
Serum C3, median (iqr), mg/dl	**-0.38**	**< 0.001**	**-0.34**	**< 0.001**
Serum C4, median (iqr), mg/dl	**-0.33**	**< 0.001**	**-0.24**	**0.004**
Anti-dsDNA antibodies, %	0.10	0.20	**0.28**	**< 0.001**
aPL antibodies, %[e]	-0.14	0.17	**-0.27**	**0.01**
Glomerulosclerosis, median (iqr), %	-0.10	0.20	**-0.16**	**0.03**
IF/TA, median (iqr), %	-0.05	0.55	-0.13	0.08
Any tubulointerstitial inflammation, %	-0.05	0.49	-0.01	0.92
Moderate to severe vascular damage, %	0.00	0.96	-0.14	0.06
Pathological activity index, median (iqr)[f]	**0.26**	**0.003**	**0.32**	**< 0.001**
Pathological chronicity index, median (iqr)[g]	-0.08	0.40	-0.18	0.05

[a] Excluding the parameters reflecting renal damage, maximum score of 37. [b] Prednisone ≥ 20 mg/d or equivalent. [c] Including azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate, rituximab. [d] Protein-creatinine ratio ≥ 1 g/g. [e] aCL antibodies, anti-β2-glycoprotein antibodies, or lupus anticoagulant detected at least twice. [f] Maximum score of 24. [g] Maximum score of 12. [h] Spearman's correlation coefficient.
ACE: angiotensin-converting enzyme; IF/TA: interstitial fibrosis and tubular atrophy; iqr: interquartile range.

Supplementary Table S3A. Characteristics of the study population by the presence of deposits of complement factors

	Glomerular deposits			Tubular deposits		
	C1q with or without C3	**C3 only**	***P***	**C1q with or without C3**	**C3 only**	***P***
Number of patients, *n*	146	23		36	51	
Age, median (iqr), years	36 (26-45)	33 (25-44)	0.49	32 (29-43)	37 (26-47)	0.53
Female sex, %	82.2	95.7	0.10	83.3	92.2	0.20
Race/ethnicity, %			0.47			0.43
White	33.6	43.5		22.2	37.3	
Black	30.1	39.1		36.1	33.3	
Hispanic	20.6	8.7		16.7	15.7	
Asian	12.3	8.7		22.2	9.8	
Other or unknown	3.4	0.0		2.8	3.9	
Past medical history, %						
Hypertension	56.9	56.5	0.98	55.6	56.9	0.90
Diabetes mellitus	5.5	4.4	0.82	8.3	2.0	0.16
Current hypertension, %	**32.0**	**5.0**	**0.01**	**58.1**	**24.4**	**0.003**
Duration of SLE, median (iqr), years	2.9 (0.4-10.5)	6.1 (1.7-10.7)	0.28	3.4 (0.3-7.0)	5.9 (1.3-11.5)	0.11
SLICC/ACR damage index, median (iqr)[a]	2 (0-4)	2 (1-6)	0.25	2 (0-5)	2 (1-4)	0.80
Medication, %						
ACE inhibitors	30.0	27.3	0.80	36.7	22.9	0.19
NSAIDs	23.9	22.7	0.91	16.7	27.1	0.29
HCQ	49.2	50.0	0.95	43.3	50.0	0.57
High-dose corticosteroids[b]	30.8	27.3	0.74	30.0	31.3	0.91
Immunosuppressives[c]	23.9	13.6	0.29	26.7	20.8	0.55
Haemoglobin, median (iqr), g/dl	10.6 (9.2-12.0)	11.2 (10.7-12.4)	0.14	**9.8 (8.9-10.6)**	**10.9 (9.4-12.4)**	**0.005**
Serum albumin, median (iqr), g/dl	3.1 (2.7-3.5)	3.2 (2.8-3.7)	0.50	2.8 (2.5-3.2)	3.2 (2.4-3.5)	0.06
Serum creatinine, median (iqr), mg/dl	0.9 (0.7-1.2)	0.9 (0.7-1.4)	0.89	1.0 (0.7-1.6)	0.8 (0.7-1.2)	0.55
eGFR, median (iqr), ml/min/1.73 m^2	93 (58-119)	88 (50-127)	0.83	81 (44-118)	93 (58-119)	0.64
Proteinuria, %[d]	74.2	71.4	0.79	74.2	75.6	0.89
Serum C3, median (iqr), mg/dl	**57 (40-73)**	**69 (57-105)**	**0.02**	**47 (36-57)**	**61 (46-73)**	**0.01**
Serum C4, median (iqr), mg/dl	**8 (6-13)**	**13 (8-20)**	**0.03**	**7 (6-9)**	**9 (7-13)**	**0.04**
Anti-dsDNA antibodies, %	82.5	76.2	0.49	93.1	86.4	0.37
aPL antibodies, %[e]	31.1	54.6	0.13	26.3	40.0	0.34
Glomerulosclerosis, median (iqr), %	5 (0-18)	5 (1-24)	0.40	6 (0-20)	5 (0-21)	0.89
IF/TA, median (iqr), %	10 (0-20)	10 (0-20)	0.74	10 (3-23)	10 (0-15)	0.48
Any tubulointerstitial inflammation, %	13.8	17.4	0.65	22.2	13.7	0.30
Moderate to severe vascular damage, %	34.3	39.1	0.65	44.4	43.1	0.90
Pathological activity index, median (iqr)[f]	7 (2-11)	3 (1-7)	0.12	**10 (6-13)**	**5 (2-11)**	**0.02**
Pathological chronicity index, median (iqr)[g]	2 (0-3)	2 (0-3)	0.98	2 (1-4)	2 (1-3)	0.99

Supplementary Table S3B. Characteristics of the study population by the presence of deposits of complement factors

	Vascular deposits		
	C1q ± C3	**C3 only**	***P***
Number of patients, *n*	38	96	
Age, median (iqr), years	35 (26-45)	37 (26-45)	0.88
Female sex, %	84.2	86.5	0.73
Race/ethnicity, %			0.21
White	29.0	41.7	
Black	42.1	25.0	
Hispanic	15.8	15.6	
Asian	13.2	12.5	
Other or unknown	0.0	5.2	
Past medical history, %			
Hypertension	57.9	59.4	0.88
Diabetes mellitus	2.6	6.3	0.40
Current hypertension, %	**46.0**	**25.3**	**0.03**
Duration of SLE, median (iqr), years	1.9 (0.4-5.6)	5.8 (0.8-12.0)	0.05
SLICC/ACR damage index, median (iqr)[a]	2 (1-5)	2 (0-5)	0.63
Medication, %			
ACE inhibitors	31.3	30.3	0.92
NSAIDs	28.1	16.9	0.17
HCQ	37.5	49.4	0.25
High-dose corticosteroids[b]	31.3	34.8	0.71
Immunosuppressives[c]	25.0	23.6	0.87
Haemoglobin, median (iqr), g/dl	**9.7 (8.8-11.1)**	**10.9 (9.7-12.1)**	**0.006**
Serum albumin, median (iqr), g/dl	**2.9 (2.4-3.3)**	**3.3 (2.7-3.5)**	**0.03**
Serum creatinine, median (iqr), mg/dl	0.9 (0.6-1.2)	0.9 (0.7-1.2)	0.44
eGFR, median (iqr), ml/min/1.73 m^2	93 (51-123)	90 (59-118)	0.32
Proteinuria, %[d]	69.4	80.7	0.18
Serum C3, median (iqr), mg/dl	**48 (37-63)**	**61 (44-83)**	**0.007**
Serum C4, median (iqr), mg/dl	**7 (6-9)**	**9 (7-15)**	**0.008**
Anti-dsDNA antibodies, %	94.1	81.7	0.09
aPL antibodies, %[e]	33.3	32.0	0.92
Glomerulosclerosis, median (iqr), %	8 (0-22)	5 (0-20)	0.70
IF/TA, median (iqr), %	10 (5-20)	10 (0-18)	0.07
Any tubulointerstitial inflammation, %	18.4	10.4	0.21
Moderate to severe vascular damage, %	47.4	36.5	0.24
Pathological activity index, median (iqr)[f]	7 (2-13)	6 (2-10)	0.21
Pathological chronicity index, median (iqr)[g]	3 (1-4)	2 (0-3)	0.08

[a] Excluding the parameters reflecting renal damage, maximum score of 37. [b] Prednisone ≥ 20 mg/d or equivalent. [c] Including azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate, rituximab. [d] Protein-creatinine ratio ≥ 1 g/g. [e] aCL antibodies, anti-β2-glycoprotein antibodies, or lupus anticoagulant detected at least twice. [f] Maximum score of 24. [g] Maximum score of 12. ACE: angiotensin-converting enzyme; IF/TA: interstitial fibrosis and tubular atrophy; iqr: interquartile range.

Supplementary Table S4A. Change in estimated glomerular filtration rate over a year and renal deposits of complement factors

	All	Class II	Class III	Class IV	Class V
Number of patients, *n*	135	18	37	47	33
Change in eGFR, median (iqr), ml/min/1.73 m^2	1.4 (-11.8; 20.0)	-2.6 (-8.3; 12.5)	-0.6 (-10.9; 15.2)	14.6 (-9.2; 32.3)	-5.4 (-12.6; 5.8)
Estimates of change in eGFR[a]					
Glomerular deposits					
Presence of C1q	**12.3 (2.0; 22.5)**	10.3 (-12.9; 33.6)	**20.4 (2.3; 38.4)**	9.1 (-14.2; 32.5)	4.0 (-15.3; 23.3)
Presence of C3	**16.6 (2.8; 30.4)**	12.8 (-12.2; 37.9)	**29.7 (8.8; 50.7)**	0.9 (-40.6; 42.4)	4.1 (-29.1; 37.2)
Intensity of C1q	**3.6 (0.2; 7.0)**	4.0 (-8.3; 16.3)	4.2 (-2.0; 10.4)	3.7 (-3.3; 10.7)	-0.4 (-7.3; 6.4)
Intensity of C3	**7.2 (3.4; 11.0)**	5.8 (-4.0; 15.6)	**9.7 (2.7; 16.7)**	4.3 (-4.1; 12.7)	6.0 (-2.1; 14.0)
Presence of C1q with or without C3	5.4 (-7.0; 17.8)	-0.8 (-34.6; 32.9)	4.1 (-20.7; 28.9)	8.4 (-16.8; 33.7)	2.9 (-18.0; 23.7)
Presence of C3 only	-5.4 (-17.8; 7.0)	0.8 (-32.9; 34.6)	-4.1 (-28.9; 20.7)	-8.4 (-33.7; 16.8)	-2.9 (-23.7; 18.0)
Tubular deposits					
Presence of C1q	**13.6 (2.4; 24.8)**	1.2 (-49.6; 52.0)	5.3 (-14.0; 24.6)	18.3 (-0.1; 36.7)	3.3 (-29.8; 36.5)
Presence of C3	3.6 (-5.0; 12.2)	-10.3 (-46.9; 26.3)	3.7 (-12.7; 20.0)	-3.3 (-20.5; 13.9)	9.0 (-6.4; 24.5)
Presence of C1q with or without C3	**15.1 (1.4; 28.8)**	10.3 (-318.3; 339.9)	6.1 (-16.9; 29.1)	**25.4 (2.8; 48.0)**	-1.4 (-45.5; 42.7)
Presence of C3 only	**-15.1 (-28.8; -1.4)**	-10.3 (-338.9; 318.3)	-6.1 (-29.1; 16.9)	**-25.4 (-48.0; -2.8)**	1.4 (-42.7; 45.5)
Vascular deposits					
Presence of C1q	4.6 (-5.8; 15.1)	-11.0 (-41.7; 19.6)	2.0 (-17.4; 21.3)	10.3 (-8.1; 28.8)	-3.1 (-25.1; 19.0)
Presence of C3	5.6 (-4.0; 15.1)	9.8 (-12.9; 32.5)	2.4 (-14.3; 19.1)	1.0 (-20.3; 22.3)	8.4 (-10.7; 27.5)
Presence of C1q with or without C3	3.2 (-7.8; 14.2)	-21.2 (-44.7; 2.4)	1.8 (-16.3; 19.9)	11.1 (-9.8; 31.9)	-5.4 (-28.7; 17.8)
Presence of C3 only	-3.2 (-14.2; 7.8)	21.2 (-2.4; 44.7)	-1.8 (-19.9; 16.3)	-11.1 (-31.9; 9.8)	5.4 (-17.8; 28.7)

[a] Estimates of change in eGFR over a year after biopsy given in ml/min/1.73 m^2 with 95% confidence intervals as dependent on the presence of deposits with the absence of deposits as the reference and as dependent on the intensity of the deposits on a scale from 0 to 4 with 0 as the reference.

Supplementary Table S4B. Change in estimated glomerular filtration rate over a year and renal deposits of complement factors

	All	Class II	Class III	Class IV	Class V
Number of patients, *n*	135	18	37	47	33
Patients with decline in eGFR, %	48.9	55.6	54.1	31.9	63.6
Odds ratios for a decline in eGFR[a]					
Glomerular deposits					
Presence of C1q	**0.28 (0.11-0.69)**	0.10 (0.01-1.10)	0.31 (0.05-1.81)	0.28 (0.05-1.48)	0.64 (0.10-3.95)
Presence of C3	**0.23 (0.06-0.86)**	0.21 (0.02-2.48)	0.25 (0.03-2.49)	0.45 (0.03-7.75)	NA[b]
Intensity of C1q	**0.76 (0.57-1.00)**	0.46 (0.15-1.44)	0.78 (0.46-1.33)	0.77 (0.46-1.29)	1.08 (0.58-1.99)
Intensity of C3	**0.57 (0.40-0.80)**	0.42 (0.16-1.14)	0.69 (0.36-1.35)	0.79 (0.43-1.46)	0.43 (0.18-1.02)
Presence of C1q with or without C3	0.47 (0.17-1.31)	0.29 (0.02-4.24)	0.47 (0.04-5.73)	0.38 (0.07-2.17)	0.80 (0.12-5.20)
Presence of C3 only	2.13 (0.77-5.92)	3.50 (0.24-51.90)	2.14 (0.17-26.33)	2.64 (0.46-15.08)	1.25 (0.19-8.13)
Tubular deposits					
Presence of C1q	**0.31 (0.11-0.83)**	NA[c]	0.81 (0.17-3.89)	0.14 (0.02-1.18)	0.55 (0.03-9.68)
Presence of C3	0.76 (0.38-1.50)	0.78 (0.04-14.75)	1.22 (0.32-4.66)	1.37 (0.38-4.94)	0.38 (0.09-1.65)
Presence of C1q with or without C3	**0.28 (0.09-0.84)**	NA[c]	0.40 (0.05-3.42)	**0.08 (0.01-0.77)**	0.88 (0.05-16.74)
Presence of C3 only	**3.62 (1.19-11.06)**	NA[c]	2.50 (0.29-21.40)	**12.38 (1.29-118.33)**	1.14 (0.06-21.87)
Vascular deposits					
Presence of C1q	0.97 (0.43-2.20)	1.75 (0.13-23.70)	1.56 (0.31-7.75)	0.55 (0.13-2.39)	2.59 (0.25-26.31)
Presence of C3	0.60 (0.28-1.29)	0.14 (0.02-1.16)	1.63 (0.42-6.36)	0.51 (0.11-2.26)	0.64 (0.10-3.95)
Presence of C1q with or without C3	1.14 (0.48-2.73)	10.00 (0.40-250.42)	1.17 (0.21-6.56)	0.64 (0.14-2.97)	3.00 (0.28-31.63)
Presence of C3 only	0.87 (0.37-2.08)	0.10 (0.00-2.50)	0.86 (0.15-4.82)	1.57 (0.34-7.32)	0.33 (0.03-3.51)

[a] Odds ratios for a decline in eGFR over a year after biopsy with 95% confidence intervals as dependent on the presence of deposits with the absence of deposits as the reference and as dependent on the intensity of the deposits on a scale from 0 to 4 with 0 as the reference. [b] Could not be calculated as all patients without these deposits had a decline in eGFR. [c] Could not be calculated as no patients with these deposits had a decline in eGFR.

Supplementary Table S5. Hazard ratios for end-stage renal disease and death and renal deposits of complement factors

	All	Class II	Class III	Class IV	Class V
Number of patients, *n*	183	21	47	69	46
Patients with end-stage renal disease or death, %	26.8	14.3	21.3	39.1	19.6
Patients with end-stage renal disease, %	24.6	9.5	21.3	37.7	15.2
Patients with death, %	7.7	4.8	0.0	13.0	8.7
Follow-up, median (iqr), years	7.5 (3.0-11.4)	7.3 (4.6-10.0)	8.8 (4.5-11.3)	5.9 (2.1-11.7)	8.0 (3.1-11.4)
Hazard ratios (95%CI)[a]					
Glomerular deposits					
Presence of C1q	0.88 (0.46-1.67)	0.51 (0.05-5.61)	0.43 (0.12-1.58)	0.93 (0.37-2.34)	1.66 (0.20-13.58)
Presence of C3	0.86 (0.38-1.92)	NA[b]	0.73 (0.15-3.67)	**0.29 (0.11-0.78)**	NA[b]
Intensity of C1q	0.99 (0.79-1.24)	0.50 (0.07-3.60)	0.71 (0.41-1.21)	0.89 (0.66-1.20)	1.61 (0.86-3.00)
Intensity of C3	0.91 (0.71-1.15)	0.94 (0.36-2.47)	0.85 (0.48-1.52)	**0.69 (0.50-0.94)**	1.44 (0.67-3.11)
Presence of C1q with or without C3	0.82 (0.38-1.78)	0.20 (0.02-2.24)	0.26 (0.05-1.31)	1.42 (0.42-4.83)	1.42 (0.17-11.59)
Presence of C3 only	1.22 (0.56-2.64)	4.96 (0.45-55.05)	3.82 (0.76-19.13)	0.71 (0.21-2.40)	0.70 (0.09-5.75)
Tubular deposits					
Presence of C1q	1.20 (0.58-2.49)	NA[c]	0.46 (0.06-3.66)	1.02 (0.42-2.44)	2.12 (0.25-18.16)
Presence of C3	0.98 (0.55-1.72)	NA[c]	0.57 (0.12-2.70)	0.84 (0.39-1.79)	0.77 (0.19-3.09)
Presence of C1q with or without C3	1.32 (0.55-3.17)	NA[c]	0.84 (0.05-13.49)	1.09 (0.39-3.10)	3.02 (0.27-33.41)
Presence of C3 only	0.76 (0.32-1.81)	NA[c]	1.19 (0.07-18.98)	0.91 (0.32-2.59)	0.33 (0.03-3.66)
Vascular deposits					
Presence of C1q	0.86 (0.40-1.84)	4.36 (0.38-49.92)	1.04 (0.22-4.91)	0.60 (0.20-1.75)	0.72 (0.09-5.89)
Presence of C3	0.91 (0.49-1.67)	NA[b]	0.73 (0.21-2.61)	0.59 (0.26-1.33)	0.84 (0.17-4.17)
Presence of C1q with or without C3	0.87 (0.39-1.94)	2.35 (0.20-27.23)	1.29 (0.24-7.08)	0.73 (0.24-2.28)	0.65 (0.08-5.37)
Presence of C3 only	1.14 (0.52-2.54)	0.43 (0.04-4.95)	0.77 (0.14-4.25)	1.37 (0.44-4.25)	1.55 (0.19-12.91)

[a] For the composite outcome of end-stage renal disease and death as dependent on the presence of deposits with the absence of deposits as the reference and as dependent on the intensity of the deposits on a scale from 0 to 4 with 0 as the reference. [b] Could not be calculated as no patients without these deposits reached the composite outcome. [c] Could not be calculated as no patients with these deposits reached the composite outcome.